Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Melanoma/Skin Cancer
•
Medical Oncology
What is your preferred adjuvant systemic treatment for a patient with isolated melanoma brain metastasis following complete resection and SRS to the tumor bed?
Related Questions
Any role for adjuvant systemic therapy for resected sebaceous skin carcinoma?
In what scenario would you consider dual IO and TKI therapy in advanced stage melanoma?
What role, if any, do biomarkers play in selecting appropriate patients for neoadjuvant cemiplimab in cutaneous squamous cell carcinoma?
What criteria do you use to determine the resectability of mucosal melanoma of the H&N region?
What scenario would flipped dosing versus standard dosing of Ipilimumab+Nivolumab be beneficial in metastatic melanoma?
Based on the results of SWOG S1801, neoadjuvant vs adjuvant pembrolizumab for resected stage IIIB-IV melanoma, are you starting to recommend neoadjuvant pembro for your patients?
How do you approach patients with early stage resected melanoma (Stage IIA) for adjuvant treatment?
How would you approach a 2 cm malignant primary cutaneous adnexal adenocarcinoma of the axilla s/p resection with positive margin who is unable to undergo additional surgery?
Do you get routine MRI brain for surveillance on patients with history of stage III melanoma?
Do you consider downstaging neoadjuvant cemipilimab for borderline resectable CSCC in order to facilitate surgical resection?